- Home
- MDXH vs TLSA Comparison
MDXH vs TLSA Comparison
Compare MDXH & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- TLSA
- Stock Information
- Founded
- MDXH 2003
- TLSA 2013
- Country
- MDXH Belgium
- TLSA United Kingdom
- Employees
- MDXH N/A
- TLSA N/A
- Industry
- MDXH
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- TLSA Health Care
- Exchange
- MDXH Nasdaq
- TLSA Nasdaq
- Market Cap
- MDXH 93.1M
- TLSA 87.8M
- IPO Year
- MDXH 2021
- TLSA 2000
- Fundamental
- Price
- MDXH $2.00
- TLSA $0.73
- Analyst Decision
- MDXH Strong Buy
- TLSA
- Analyst Count
- MDXH 2
- TLSA 0
- Target Price
- MDXH $7.00
- TLSA N/A
- AVG Volume (30 Days)
- MDXH 136.8K
- TLSA 474.1K
- Earning Date
- MDXH 02-26-2025
- TLSA 01-21-2025
- Dividend Yield
- MDXH N/A
- TLSA N/A
- EPS Growth
- MDXH N/A
- TLSA N/A
- EPS
- MDXH N/A
- TLSA N/A
- Revenue
- MDXH $84,708,000.00
- TLSA N/A
- Revenue This Year
- MDXH $27.57
- TLSA N/A
- Revenue Next Year
- MDXH $20.09
- TLSA N/A
- P/E Ratio
- MDXH N/A
- TLSA N/A
- Revenue Growth
- MDXH 33.01
- TLSA N/A
- 52 Week Low
- MDXH $1.55
- TLSA $0.41
- 52 Week High
- MDXH $4.44
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- MDXH 40.19
- TLSA 43.15
- Support Level
- MDXH $1.96
- TLSA $0.63
- Resistance Level
- MDXH $2.25
- TLSA $0.95
- Average True Range (ATR)
- MDXH 0.18
- TLSA 0.08
- MACD
- MDXH -0.05
- TLSA 0.01
- Stochastic Oscillator
- MDXH 5.71
- TLSA 29.69
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.